Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 18/20 | 0.48 |
| ▸ | KDM6B | O15054 | 7/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KDM4A | O75164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980592 | 0.85 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL10467610 | 0.85 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL9018158 | 0.83 | SIRT3 (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL3880004 | 0.82 | KDM4C (0.50) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL123203 | 0.82 | KDM4C (0.51) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL30465694 | 0.82 | KDM4C (0.51) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL7509912 | 0.81 | KDM4C (0.48) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL2479238 | 0.81 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL3931892 | 0.81 | KDM4C (0.48) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL7263236 | 0.81 | KDM4C (0.48) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377080-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220378757-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-01 | — | — | US | disclosed |
| EP-3131876-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-1585481-A2 | PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004064721-A2 | A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377080-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | KDM4C 4191/4885KDM6B 2534/4885KDM4D 4616/4885 |
| US-20220378757-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | KDM4C 4191/4885KDM6B 2534/4885KDM4D 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.